|
US20030190307A1
(en)
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
|
TR199901968T2
(xx)
*
|
1996-12-24 |
1999-12-21 |
Biogen, Inc. |
Sabit s�v� interferon form�lleri.
|
|
CA2304808C
(en)
|
1997-09-23 |
2011-03-22 |
Michael Tschope |
Liquid interferon-.beta. formulations
|
|
JP4635340B2
(ja)
*
|
1999-05-31 |
2011-02-23 |
三菱化学株式会社 |
Ｈｇｆ凍結乾燥製剤
|
|
US6887462B2
(en)
*
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
|
AR034749A1
(es)
*
|
2001-07-09 |
2004-03-17 |
Schering Ag |
Formulaciones de interferon beta humano
|
|
DE60232017D1
(de)
|
2001-12-21 |
2009-05-28 |
Novo Nordisk Healthcare Ag |
Flüssige zusammensetzung aus faktor vii polypeptiden
|
|
EP1475098B1
(en)
*
|
2002-01-18 |
2015-08-05 |
Asahi Kasei Pharma Corporation |
High-concentration preparation of soluble thrombomodulin
|
|
PL207018B1
(pl)
|
2002-06-21 |
2010-10-29 |
Novo Nordisk Helth Care Ag |
Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7897734B2
(en)
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
TWI272948B
(en)
|
2003-05-01 |
2007-02-11 |
Ares Trading Sa |
HSA-free stabilized interferon liquid formulations
|
|
AR044302A1
(es)
|
2003-05-13 |
2005-09-07 |
Ares Trading Sa |
Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
|
|
CN1780638B
(zh)
|
2003-05-23 |
2010-04-14 |
诺和诺德医疗保健公司 |
氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
|
|
CN1318087C
(zh)
*
|
2003-06-06 |
2007-05-30 |
北京三诺佳邑生物技术有限责任公司 |
去白蛋白神经生长因子制剂
|
|
RU2388460C2
(ru)
|
2003-08-14 |
2010-05-10 |
Ново Нордиск Хелс Кеа Аг |
Жидкая водная фармацевтическая композиция, содержащая полипептид фактора vii
|
|
CN100548228C
(zh)
*
|
2003-11-13 |
2009-10-14 |
阿尔扎公司 |
用于透皮递送的组合物和装置
|
|
EP1532983A1
(en)
*
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
|
EP2298287B1
(en)
|
2003-12-19 |
2018-04-11 |
Novo Nordisk Health Care AG |
Stabilised compositions of factor VII polypeptides
|
|
EP1750750B1
(en)
*
|
2004-06-01 |
2012-02-01 |
Ares Trading S.A. |
Method of stabilizing proteins
|
|
WO2006022301A1
(ja)
*
|
2004-08-24 |
2006-03-02 |
Daiichi Asubio Pharma Co., Ltd. |
生理活性ペプチド液状製剤
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
AU2005304486B2
(en)
*
|
2004-11-10 |
2011-08-11 |
Novartis Vaccines And Diagnostics Inc. |
Deamidated interferon-beta
|
|
US8784399B2
(en)
*
|
2005-01-12 |
2014-07-22 |
Biogen Idec Ma Inc. |
Method for delivering interferon-β
|
|
AU2006206272A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Alza Corporation |
Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
|
|
EP2264162A1
(en)
|
2005-07-02 |
2010-12-22 |
Arecor Limited |
Stable aqueous systems comprising proteins
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
|
US8277845B2
(en)
*
|
2007-12-04 |
2012-10-02 |
Remedy Pharmaceuticals, Inc. |
Formulations and methods for lyophilization and lyophilates provided thereby
|
|
CN101878043A
(zh)
|
2007-12-20 |
2010-11-03 |
默克雪兰诺有限公司 |
PEG-干扰素-β制剂
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
JP2011519848A
(ja)
|
2008-05-01 |
2011-07-14 |
アレコー リミテッド |
タンパク質製剤
|
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
BRPI0919288A2
(pt)
|
2008-09-10 |
2015-12-15 |
Boehring Ingelheim Internat Gmbh |
teriapia de combinação para tratamento de diabetes e condições relacionadas.
|
|
DE102008051574A1
(de)
|
2008-10-14 |
2010-04-15 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren zur Herstellung von Interferon-beta und deren Varianten
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
DE102009032179A1
(de)
|
2009-07-07 |
2011-01-13 |
Biogenerix Ag |
Verfahren zur Reinigung von Interferon beta
|
|
PH12012501037A1
(en)
|
2009-11-27 |
2013-01-14 |
Boehringer Ingelheim Int |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
AU2011212440B2
(en)
|
2010-02-04 |
2015-01-22 |
Csl Behring Ag |
Immunoglobulin preparation
|
|
EP2361636A1
(en)
|
2010-02-26 |
2011-08-31 |
CSL Behring AG |
Immunoglobulin preparation and storage system for an immunoglobulin preparation
|
|
DE102010011430A1
(de)
*
|
2010-03-15 |
2011-09-15 |
Kurt Koch |
Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
|
|
CA2797310C
(en)
|
2010-05-05 |
2020-03-31 |
Boehringer Ingelheim International Gmbh |
Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
|
|
KR20230051307A
(ko)
|
2010-06-24 |
2023-04-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
EP2649993B1
(en)
|
2010-12-09 |
2017-04-05 |
Maruishi Pharmaceutical Co., Ltd. |
Stabilizer of acetaminophen
|
|
WO2012125809A1
(en)
|
2011-03-15 |
2012-09-20 |
Biogen Idec Inc. |
Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
|
|
ES2713566T3
(es)
|
2011-07-15 |
2019-05-22 |
Boehringer Ingelheim Int |
Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
WO2013159057A1
(en)
*
|
2012-04-19 |
2013-10-24 |
C. R. Bard, Inc. |
Infusates with enhanced ph stability under ethylene oxide sterilization
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
ITMI20120913A1
(it)
|
2012-05-28 |
2013-11-29 |
Nicoletta Maxia |
Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
|
|
CN103143000B
(zh)
*
|
2013-03-07 |
2014-11-05 |
安徽安科生物工程（集团）股份有限公司 |
一种重组人干扰素α2b制剂
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
JP2014208669A
(ja)
*
|
2014-06-17 |
2014-11-06 |
株式会社スリー・ディー・マトリックス |
タンパク質の凝集抑制剤
|
|
CA2968915A1
(en)
|
2014-12-03 |
2016-06-09 |
Csl Behring Ag |
Pharmaceutical product with increased stability comprising immunoglobulins
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
KR101943160B1
(ko)
*
|
2016-10-06 |
2019-01-30 |
에이비온 주식회사 |
인터페론 베타 변이체의 안정화 제제
|
|
SI3672631T1
(sl)
|
2017-08-22 |
2023-06-30 |
Biogen Ma Inc. |
Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
|
|
KR102731889B1
(ko)
*
|
2019-07-18 |
2024-11-19 |
에이비온 주식회사 |
2당화된 인터페론-베타 단백질의 정제 방법
|
|
CN110714051B
(zh)
*
|
2019-11-20 |
2023-04-07 |
迈克生物股份有限公司 |
蛋白c活性测定试剂盒
|
|
WO2021221485A1
(ko)
*
|
2020-04-29 |
2021-11-04 |
에이비온 주식회사 |
이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법
|
|
EP4400432A3
(en)
*
|
2021-03-30 |
2024-09-18 |
SCHOTT Pharma Schweiz AG |
System for low-temperature storage of a pharmaceutical composi-tion, liquid composition, method and uses
|
|
CN114177273B
(zh)
*
|
2021-11-29 |
2024-05-28 |
苏州人本药业有限公司 |
一种含有神经毒素的液体制剂及其制备方法
|
|
US20230210857A1
(en)
*
|
2021-12-27 |
2023-07-06 |
Enalare Therapeutics Inc. |
Respiratory stimulant parenteral formulations
|